Track 6: Third Annual Kinase Inhibitors
Intercontinental Hotel Boston Massachusetts
Track 6: Third Annual Kinase Inhibitors
Cambridge Healthtech Institute 

Schedule of Presentations:

Monday, November 2, 2009
12:30:00 Registration
14:00:00 Chairperson’s Opening Remarks
14:10:00 Safety and Toxicology Challenges on the Way to a Kinase Inhibitor Drug Development Keynote Presentation Anja J. Stauber
14:15:00 Development – Lessons Learned
14:40:00 Developing a Novel Checkpoint Kinase Inhibitor Sonya Zabludoff
15:10:00 Aurora A Inhibitor MLN8237: From Discovery to Development Christopher Claiborne
15:40:00 Networking Refreshment Break in the Exhibit Hall
16:20:00 Title to be Announced Peter A. Petillo
16:25:00 Improving Efficacy
16:50:00 Comparison of in vitro and Cellular IC50 Inhibitory Profiles of 7 Clinical Kinase Inhibitors on 16 Oncologically Relevant Kinases Jan E. Ehlert
17:05:00 Sponsored Presentation
17:20:00 Identifying Allosteric Modulators of Pyruvate Kinase Orthologs with Quantitative High-throughput Screening Douglas Auld
17:50:00 Radiosensitize Human Cancer Cells by an scFv against the DNA-Dependent Protein Kinase Shuyi Li
18:20:00 Close of Day
Tuesday, November 3, 2009
07:30:00 Continental Breakfast Breakout Discussions
07:35:00 Kinase Inhibitor Chemistry
08:35:00 Chairperson’s Remarks
08:40:00 Structure-Guided Design of AP24534, a Potent Orally Active Inhibitor BCR-ABLT315I and other Resistant Mutants William Shakespeare
09:10:00 Structure-guided Discovery of SGX523, a Potent and Exquisitely Selective ATP-competitive Inhibitor of the cMET Receptor Tyrosine Kinase Christopher R. Smith
09:40:00 The Discovery and Optimization of Highly Selective p38 Inhibitors Martha J. Kelly
10:10:00 Networking Coffee Break in the Exhibit Hall
10:15:00 Advances in Targeting Tumors
10:55:00 CX-4945, a First in Class Selective Inhibitor of CK2, Effectively Blocks Multiple CK2-Mediated Signaling Pathways, including Akt, and Demonstrates Significant Antiproliferative and Antitumor Activities Kenna Anderes
11:25:00 Cellular Target Profiling and Quantitative Phosphoproteomics Reveal Insight into a Drug’s Efficiency and Cellular Mode of Action Jutta Fritz
11:55:00 Development of an Antibody Drug Conjugate Targeting The EphA2 Receptor Tyrosine Kinase Dowdy Jackson
12:25:00 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own
12:30:00 Beyond Cancer – Novel Emerging Targets
13:55:00 Chairperson’s Remarks
14:00:00 Targeting Bruton’s Tyrosine Kinase Lee Honigberg
14:30:00 Know Pain, Know Gain: Development of a Selective Epsilon PKC Inhibitor for the Treatment of Pain James Tomlinson
15:00:00 Networking Ice Cream Refreshment Break in Exhibit Hall (Last Chance for Viewing)
15:40:00 Targeting Diabetes Allan Saltiel
16:40:00 Title to be Announced M. Dror Michaelson
17:10:00 Close of Conference
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.